TriangleCD22CART cell (NCT04815356)
CD22CART cell trial for Hairy Cell Leukemia (NCT04815356). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Hairy cell leukemia is rare and usually gentle; most people respond to a week of chemotherapy and stay well for years. But a variant form shrugs it off, and once targeted drugs fail, survival is a couple of years.
The idea: turn CAR T cells, proven in other B-cell leukemias, on this one.
Hairy cells are brightly coated in a protein called CD22. The National Cancer Institute team that built the first anti-CD22 drug for this disease now fits a patient's own T cells with a receptor for it. After chemotherapy makes room, one infusion goes in.
Robert Kreitman leads it at the NIH Clinical Center in Bethesda, for adults out of standard options, asking what dose is safe. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.